Study of the osteoprotegerin/receptor activator of nuclear factor-kB ligand system association with inflammation and atherosclerosis in systemic sclerosis

References

• Abu-Shakra M , Lee P. 1995. Mortality in systemic sclerosis: A comparison with the general population. J Rheumatol, 22, 2100–2102
   PubMed Web of Science ®Google Scholar
• Au K , Singh MK , Bodukam V , et al. 2011. Atherosclerosis in systemic sclerosis: A systematic review and meta‐analysis. Arthritis Rheum, 63, 2078–2090
   PubMedGoogle Scholar
• Breland UM , Hollan I , Saatvedt K , et al. 2010. Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease. Rheumatology, 49, 1118–1127
   PubMed Web of Science ®Google Scholar
• Cannarile F , Valentini V , Mirabelli G , et al. 2015. Cardiovascular disease in systemic sclerosis. Annals of Translational Medicine, 3, 8
   PubMed Web of Science ®Google Scholar
• Charles C , Clements P , Furst DE. 2006. Systemic sclerosis: hypothesis-driven treatment strategies. The Lancet, 367, 1683–1691
   PubMed Web of Science ®Google Scholar
• Cheng K-S , Tiwari A , Boutin A , et al. 2003. Carotid and femoral arterial wall mechanics in scleroderma. Rheumatology, 42, 1299–1305
   PubMed Web of Science ®Google Scholar
• Collin-Osdoby P. 2004. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res, 95, 1046–1057
   PubMed Web of Science ®Google Scholar
• Dhore CR , Cleutjens JP , Lutgens E , et al. 2001. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol, 21, 1998–2003
   PubMed Web of Science ®Google Scholar
• Doria A , Shoenfeld Y , Wu R , et al. 2003. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis, 62, 1071–1077
   PubMed Web of Science ®Google Scholar
• Dovio A , Data V , Carignola R , et al. 2008. Circulating osteoprotegerin and soluble RANK ligand in systemic sclerosis. J Rheumatol, 35, 2206–2213
   PubMed Web of Science ®Google Scholar
• Falk E . 2006. Pathogenesis of atherosclerosis. J Am Coll Cardiol, 47, C7–C12
   PubMed Web of Science ®Google Scholar
• Geusens P . 2012. The role of RANK ligand/osteoprotegerin in rheumatoid arthritis. Ther Adv Musculoskelet Dis, 4, 225–233
   PubMedGoogle Scholar
• Golledge J , McCann M , Mangan S , et al. 2004. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke, 35, 1636–1641
   PubMed Web of Science ®Google Scholar
• Herrick A , Cerinic MM . 2001. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol, 19, 4–8
   PubMed Web of Science ®Google Scholar
• Ho M , Veale D , Eastmond C , et al. 2000. Macrovascular disease and systemic sclerosis. Ann Rheum Dis, 59, 39–43
   PubMed Web of Science ®Google Scholar
• Hofbauer LC , Heufelder AE . 2001. Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology. J Mol Med, 79, 243–253
   PubMed Web of Science ®Google Scholar
• Hofbauer LC , Schoppet M . 2001. Osteoprotegerin: A link between osteoporosis and arterial calcification? The Lancet, 358, 257–259
   PubMed Web of Science ®Google Scholar
• Jimenez SA , Derk CT . 2004. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med, 140, 37–50
   PubMed Web of Science ®Google Scholar
• Kelesidis T , Kendall MA , Yang OO , et al. 2013. Perturbations of circulating levels of RANKL-osteoprotegerin axis in relation to lipids and progression of atherosclerosis in HIV-infected and-uninfected adults: ACTG NWCS 332/A5078 Study. AIDS Res Hum Retroviruses, 29, 938–948
   PubMed Web of Science ®Google Scholar
• Kiechl S , Schett G , Schwaiger J , et al. 2007. Soluble receptor activator of nuclear factor-κB ligand and risk for cardiovascular disease. Circulation, 116, 385–391
   PubMed Web of Science ®Google Scholar
• Kiel DP , Kauppila LI , Cupples LA , et al. 2001. Bone loss and the progression of abdominal aortic calcification over a 25 year period: The Framingham Heart Study. Calcif Tissue Int, 68, 271–276
   PubMed Web of Science ®Google Scholar
• LeRoy EC . 1996. Systemic sclerosis: A vascular perspective. Rheum Dis Clin America, 22, 675–694
   PubMed Web of Science ®Google Scholar
• LeRoy EC , Black C , Fleischmajer R , et al. 1988. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol, 15, 202
   PubMed Web of Science ®Google Scholar
• Masi AT , Rodnan G , Medsger Jr T , et al. 1980. Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum, 23, 581–590
   PubMed Web of Science ®Google Scholar
• Matsuura E , Kobayashi K , Lopez LR . 2009. Atherosclerosis in autoimmune diseases. Curr Rheumatol Rep, 11, 61–69
   PubMedGoogle Scholar
• Mayes MD , Lacey JV , Beebe‐Dimmer J , et al. 2003. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum, 48, 2246–2255
   PubMed Web of Science ®Google Scholar
• Medsger T , Bombardieri S , Czirjak L , et al. 2003. Assessment of disease severity and prognosis. Clin Exp Rheumatol, 21, S42–S46
   PubMed Web of Science ®Google Scholar
• Medsger TA , Masi AT , Rodnan GP , et al. 1971. Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med, 75, 369–376
   PubMed Web of Science ®Google Scholar
• Medsger TA , Silman AJ , Steen VD, et al. 1999. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol, 26, 2159–2167.
   Google Scholar
• Motegi S , Toki S , Hattori T , et al. 2014. No association of atherosclerosis with digital ulcers in Japanese patients with systemic sclerosis: Evaluation of carotid intima‐media thickness and plaque characteristics. J Dermatol, 41, 604–608
   PubMed Web of Science ®Google Scholar
• Nybo M , Rasmussen LM . 2008. The capability of plasma osteoprotegerin as a predictor of cardiovascular disease: A systematic literature review. European Journal of Endocrinology, 159, 603–608
   PubMed Web of Science ®Google Scholar
• Papadopouli AE , Klonaris CN , Theocharis SE . 2008. Role of OPG-RANKL-RANK axis on the vasculature. Histol Histopathol, 23, 497–506.
   Google Scholar
• Pettit AR , Walsh NC , Manning C , et al. 2006. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford), 45, 1068–1076
   PubMed Web of Science ®Google Scholar
• Sawabe M . 2010. Vascular aging: From molecular mechanism to clinical significance. Geriatr Gerontol Int, 10, S213–S220
   PubMed Web of Science ®Google Scholar
• Schoppet M , Al-Fakhri N , Franke FE , et al. 2004. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-κB ligand in Monckeberg’s sclerosis and atherosclerosis. J Clin Endocrinol Metabolism, 89, 4104–4112
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y , Gerli R , Doria A , et al. 2005. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation, 112, 3337–3347
   PubMed Web of Science ®Google Scholar
• Slobodin G , Pavlotzky E , Panov J , et al. 2008. Endothelin-1 does not change the function of monocyte-derived dendritic cells grown from patients with systemic sclerosis. Immunol Invest, 37, 841–848
   PubMed Web of Science ®Google Scholar
• Souza PPC , Lerner UH . 2013. The role of cytokines in inflammatory bone loss. Immunol Invest, 42, 555–622
   PubMed Web of Science ®Google Scholar
• Tsifetaki N , Georgiadis A , Alamanos Y , et al. 2010. Subclinical atherosclerosis in scleroderma patients. Scand J Rheumatol, 39, 326–329
   PubMed Web of Science ®Google Scholar
• Van Campenhout A , Golledge J . 2009. Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis, 204, 321–329
   PubMed Web of Science ®Google Scholar
• Vega D , Maalouf NM , Sakhaee K . 2007. CLINICAL Review #: The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab, 92, 4514–4521
   PubMed Web of Science ®Google Scholar
• Venuraju SM , Yerramasu A , Corder R , Lahiri A . 2010. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol, 55, 2049–2061
   PubMed Web of Science ®Google Scholar